Bonner Carolyn F. 4

What Happened
Carolyn F. Bonner, President and Chief Financial Officer of Medicus Pharma Ltd. (MDCX), was granted 250,000 derivative securities (an option/award) on June 3, 2026. The filing reports an acquisition at $0.00 per share (no cash paid at grant). This is a grant of equity-linked compensation rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
• Transaction type/code: A (Grant/Award); 250,000 derivative shares granted at $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The option vests quarterly in four equal installments over one year (grants begin vesting after issuance).
• No sale or immediate exercise reported; no 10b5-1 plan or tax-withholding notation in the supplied details.

Context

• This report documents an equity award (derivative/option grant). Such grants are common executive compensation and do not by themselves indicate buying or selling activity in the open market.
• Key terms that affect value (exercise/strike price, expiration) are not shown in the provided excerpt; value realization will depend on those terms and future vesting/exercise events.